Login Register Cart 0
Research Article

黄葵胶囊对糖尿病肾病模型大鼠肾脏组织SPARC表达的影响

卷 19, 期 4, 2019

页: [211 - 215] 页: 5

弟呕挨: 10.2174/1566523219666190925112249

价格: $65

摘要

目的：研究黄葵胶囊对糖尿病肾病肾脏组织SPARC表达的影响。 方法：SD大鼠分为三组：正常对照组，未治疗的DN组和HKC治疗的DN组。通过血清肌酐，血尿素氮，24小时尿蛋白和SPARC的表达，评价HKC对链脲佐菌素诱导的DN大鼠的治疗作用及潜在的分子机制。通过苏木精-伊红（HE）染色观察到肾脏组织的病理变化。此外，蛋白质印迹和定量实时聚合酶链反应（qRT-PCR）用于检测SPARC的变化。 结果：本研究旨在探讨HKC对SD大鼠模型DN的影响及其分子机制。我们的结果表明，用HKC治疗的大鼠的全身状态得到改善，肌酐，血尿素氮和24小时尿蛋白水平降低。肾功能恶化由于HKC治疗而延迟。利用HE染色观察HKC可以改善DN大鼠肾脏组织的组织病理学发现，包括肾纤维化。 Western blot和qRT-PCR结果显示，HKC可抑制DN大鼠模型中SPARC的表达。 结论：本研究结果表明，HKC抑制SPARC水平，对DN具有显着的治疗作用。

关键词: 黄葵胶囊，糖尿病肾病，SPARC，糖尿病，中医，肾功能。

« Previous Next »
图形摘要

[1]
Adeshara KA, Diwan AG, Tupe RS. Diabetes and complications: Cellular signaling pathways, current understanding and targeted therapies. Curr Drug Targets 2016; 17(11): 1309-28.
[http://dx.doi.org/10.2174/1389450117666151209124007] [PMID: 26648059]
[2]
Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. N Engl J Med 2003; 348(25): 2543-56.
[http://dx.doi.org/10.1056/NEJMra022296] [PMID: 12815141]
[3]
Cheng L, Wang P, Tian R, et al. LncRNA2Target v2.0: A comprehensive database for target genes of lncRNAs in human and mouse. Nucleic Acids Res 2019; 47(D1): D140-4.
[http://dx.doi.org/10.1093/nar/gky1051] [PMID: 30380072]
[4]
Cheng L, Hu Y, Sun J, Zhou M, Jiang Q. DincRNA: A comprehensive web-based bioinformatics toolkit for exploring disease associations and ncRNA function. Bioinformatics 2018; 34(11): 1953-6.
[http://dx.doi.org/10.1093/bioinformatics/bty002] [PMID: 29365045]
[5]
Lane TF, Sage EH. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J 1994; 8(2): 163-73.
[http://dx.doi.org/10.1096/fasebj.8.2.8119487] [PMID: 8119487]
[6]
Jørgensen LH, Jepsen PL, Boysen A, et al. SPARC Interacts with actin in skeletal muscle in vitro and in vivo. Am J Pathol 2017; 187(2): 457-74.
[http://dx.doi.org/10.1016/j.ajpath.2016.10.013] [PMID: 27908613]
[7]
Camino AM, Atorrasagasti C, Maccio D, et al. Adenovirus-mediated inhibition of SPARC attenuates liver fibrosis in rats. J Gene Med 2008; 10(9): 993-1004.
[http://dx.doi.org/10.1002/jgm.1228] [PMID: 18615449]
[8]
Wong SL, Sukkar MB. The SPARC protein: An overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease. Br J Pharmacol 2017; 174(1): 3-14.
[http://dx.doi.org/10.1111/bph.13653] [PMID: 27759879]
[9]
Kos K, Wong S, Tan B, et al. Regulation of the fibrosis and angiogenesis promoter SPARC/osteonectin in human adipose tissue by weight change, leptin, insulin, and glucose. Diabetes 2009; 58(8): 1780-8.
[http://dx.doi.org/10.2337/db09-0211] [PMID: 19509023]
[10]
Takahashi M, Nagaretani H, Funahashi T, et al. The expression of SPARC in adipose tissue and its increased plasma concentration in patients with coronary artery disease. Obes Res 2001; 9(7): 388-93.
[http://dx.doi.org/10.1038/oby.2001.50] [PMID: 11445660]
[11]
Tseng C, Kolonin MG. Proteolytic isoforms of SPARC induce adipose stromal cell mobilization in obesity. Stem Cells 2016; 34(1): 174-90.
[http://dx.doi.org/10.1002/stem.2192] [PMID: 26381424]
[12]
Li P, Chen YZ, Lin HL, et al. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: Study protocol for a randomized controlled trial. Trials 2017; 18(1): 170.
[http://dx.doi.org/10.1186/s13063-016-1774-6] [PMID: 28395659]
[13]
Ge J, Miao JJ, Sun XY, Yu JY. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats. J Ethnopharmacol 2016; 189: 238-49.
[http://dx.doi.org/10.1016/j.jep.2016.05.033] [PMID: 27224243]
[14]
Mao ZM, Shen SM, Wan YG, et al. Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to α-lipoic acid. J Ethnopharmacol 2015; 173: 256-65.
[http://dx.doi.org/10.1016/j.jep.2015.07.036] [PMID: 26226437]
[15]
Cai HD, Su SL, Qian DW, et al. Renal protective effect and action mechanism of Huangkui capsule and its main five flavonoids. J Ethnopharmacol 2017; 206: 152-9.
[http://dx.doi.org/10.1016/j.jep.2017.02.046] [PMID: 28408246]
[16]
Maezawa Y, Yokote K, Sonezaki K, et al. Influence of C-peptide on early glomerular changes in diabetic mice. Diabetes Metab Res Rev 2006; 22(4): 313-22.
[http://dx.doi.org/10.1002/dmrr.612] [PMID: 16389646]
[17]
Liu X, Liu L, Chen P, et al. Clinical trials of traditional Chinese medicine in the treatment of diabetic nephropathy--a systematic review based on a subgroup analysis. J Ethnopharmacol 2014; 151(2): 810-9.
[http://dx.doi.org/10.1016/j.jep.2013.11.028] [PMID: 24296085]
[18]
Zhuang Q, Cheng K, Ming Y. CX3CL1/CX3CR1 axis, as the therapeutic potential in renal diseases: Friend or foe. Curr Gene Ther 2017; 17(6): 442-52.
[http://dx.doi.org/10.2174/1566523218666180214092536] [PMID: 29446734]
[19]
Yang X, Mou S. Role of immune cells in diabetic kidney disease. Curr Gene Ther 2017; 17(6): 424-33.
[http://dx.doi.org/10.2174/1566523218666180214100351] [PMID: 29446740]
[20]
Taneda S, Pippin JW, Sage EH, et al. Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol 2003; 14(4): 968-80.
[http://dx.doi.org/10.1097/01.ASN.0000054498.83125.90] [PMID: 12660331]
[21]
Socha MJ, Manhiani M, Said N, Imig JD, Motamed K. Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. Am J Pathol 2007; 171(4): 1104-12.
[http://dx.doi.org/10.2353/ajpath.2007.061273] [PMID: 17717147]
[22]
Gilbert RE, McNally PG, Cox A, et al. SPARC gene expression is reduced in early diabetes-related kidney growth. Kidney Int 1995; 48(4): 1216-25.
[http://dx.doi.org/10.1038/ki.1995.405] [PMID: 8569083]
[23]
Munjal ID, McLean NV, Grant MB, Blake DA. Differences in the synthesis of secreted proteins in human retinal endothelial cells of diabetic and nondiabetic origin. Curr Eye Res 1994; 13(4): 303-10.
[http://dx.doi.org/10.3109/02713689408995792] [PMID: 8033591]
[24]
Jandeleit-Dahm K, Rumble J, Cox AJ, et al. SPARC gene expression is increased in diabetes-related mesenteric vascular hypertrophy. Microvasc Res 2000; 59(1): 61-71.
[http://dx.doi.org/10.1006/mvre.1999.2189] [PMID: 10625572]
[25]
Wang Z, Song HY, An MM, Zhu LL. Association of serum SPARC level with severity of coronary artery lesion in type 2 diabetic patients with coronary heart disease. Int J Clin Exp Med 2015; 8(10): 19290-6.
[PMID: 26770566]
[26]
Xin C, Xia Z, Jiang C, Lin M, Li G. Xiaokeping mixture inhibits diabetic nephropathy in streptozotocin-induced rats through blocking TGF-β1/Smad7 signaling. Drug Des Devel Ther 2015; 9: 6269-74.
[http://dx.doi.org/10.2147/DDDT.S93964] [PMID: 26664048]
[27]
Han H, Cao A, Wang L, et al. Huangqi decoction ameliorates streptozotocin-induced rat diabetic nephropathy through antioxidant and regulation of the TGF-β/MAPK/PPAR-γ signaling. Cell Physiol Biochem 2017; 42(5): 1934-44.
[http://dx.doi.org/10.1159/000479834] [PMID: 28793292]
[28]
Zhang N, Gao Y, Zou D, et al. Effects of chinese medicine tong xinluo on diabetic nephropathy via inhibiting TGF- β 1-Induced epithelial-to-mesenchymal transition. Evid Based Complement Alternat Med 2014; 2014123497
[http://dx.doi.org/10.1155/2014/123497] [PMID: 24864150]

Rights & Permissions Print Cite
Article Metrics
33
5
© 2024 Bentham Science Publishers | Privacy Policy